Last updated on May 2020

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

Brief description of study

Open label, single arm, multicenter phase II trial.

Detailed Study Description

Preemptive therapy with Venetoclax for high risk stage A Chronic Lymphoid Leukemia patients, a phase II trial of the FILO group.

PREVENE (PREemptive VENEtoclax) trial.

Clinical Study Identifier: NCT03766763

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.